Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study
暂无分享,去创建一个
M. Kozal | T. Kyriakides | M. Landry | S. Shenoi | L. Barakat | E. Helou
[1] E. Poveda,et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? , 2016, The Journal of antimicrobial chemotherapy.
[2] B. Ledergerber,et al. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study , 2015, PloS one.
[3] CalcagnoAndrea,et al. HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients , 2015 .
[4] Art-Cc. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients , 2015 .
[5] P. Harrigan,et al. Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients , 2014, Antimicrobial Agents and Chemotherapy.
[6] J. Sterne,et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. , 2014, AIDS.
[7] B. Ledergerber,et al. Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study , 2014, Journal of the International AIDS Society.
[8] O. Dosekun,et al. Service impact of a change in HIV-1 viral load quantification assay , 2014, Journal of the International AIDS Society.
[9] R. Weber,et al. Association of Alcohol Consumption and HIV Surrogate Markers in Participants of the Swiss HIV Cohort Study , 2013, Journal of acquired immune deficiency syndromes.
[10] Stefan Esser,et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. , 2013, The Journal of infectious diseases.
[11] F. García García,et al. Quantification of Viral Loads Lower than 50 Copies per Milliliter by Use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, Version 2.0, Can Predict the Likelihood of Subsequent Virological Rebound to >50 Copies per Milliliter , 2013, Journal of Clinical Microbiology.
[12] J. Sánchez-Payá,et al. Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation , 2013, Journal of acquired immune deficiency syndromes.
[13] Brian R Wood,et al. Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL , 2012, PloS one.
[14] C. Charpentier,et al. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. , 2012, The Journal of antimicrobial chemotherapy.
[15] S. Leone,et al. Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAART-Treated Patients and Risk of Virological Failure , 2012, Journal of acquired immune deficiency syndromes.
[16] A. Phillips,et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] A. Kagee,et al. Common mental health problems and antiretroviral therapy adherence , 2011, AIDS care.
[18] K. Brown,et al. Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test and Identification of Rare Polymorphisms Potentially Affecting Assay Performance , 2010, Journal of Clinical Microbiology.
[19] R. Delgado,et al. Detection of HIV-1 at between 20 and 49 Copies per Milliliter by the Cobas TaqMan HIV-1 v2.0 Assay Is Associated with Higher Pretherapy Viral Load and Less Time on Antiretroviral Therapy , 2010, Journal of Clinical Microbiology.
[20] P. Massip,et al. HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy , 2009, PloS one.
[21] J. Montaner,et al. Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor Assay , 2009, Journal of acquired immune deficiency syndromes.
[22] H. Ullum,et al. Residual Viraemia in HIV‐1‐Infected Patients with Plasma Viral Load ≤20 copies/ml is Associated with Increased Blood Levels of Soluble Immune Activation Markers , 2008, Scandinavian journal of immunology.
[23] Claus O Wilke,et al. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART , 2008, BMC infectious diseases.
[24] D. Nickle,et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.
[25] H. Ullum,et al. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.
[26] Z. Grossman,et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia , 2004, AIDS.
[27] A. Lazzarin,et al. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. , 2012, The Journal of antimicrobial chemotherapy.